BMEA250117P500
- 0.00
- 0.000.00%
Biomea Fusion Newsroom
Barclays Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $30
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target
Biomea Fusion's Innovative Diabetes Therapy Boosts Buy Rating With Promising Preclinical Data on Icovamenib
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
J.P. Morgan Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11